The divergent DSL ligand Dll3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands - PubMed (original) (raw)
The divergent DSL ligand Dll3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands
Ena Ladi et al. J Cell Biol. 2005.
Abstract
Mutations in the DSL (Delta, Serrate, Lag2) Notch (N) ligand Delta-like (Dll) 3 cause skeletal abnormalities in spondylocostal dysostosis, which is consistent with a critical role for N signaling during somitogenesis. Understanding how Dll3 functions is complicated by reports that DSL ligands both activate and inhibit N signaling. In contrast to other DSL ligands, we show that Dll3 does not activate N signaling in multiple assays. Consistent with these findings, Dll3 does not bind to cells expressing any of the four N receptors, and N1 does not bind Dll3-expressing cells. However, in a cell-autonomous manner, Dll3 suppressed N signaling, as was found for other DSL ligands. Therefore, Dll3 functions not as an activator as previously reported but rather as a dedicated inhibitor of N signaling. As an N antagonist, Dll3 promoted Xenopus laevis neurogenesis and inhibited glial differentiation of mouse neural progenitors. Finally, together with the modulator lunatic fringe, Dll3 altered N signaling levels that were induced by other DSL ligands.
Figures
Figure 1.
Dll3 does not activate N signaling in trans. (A) Cell surface expression of HA-tagged Dll1, Dll3, and Dll1 + Dll3 L cell lines was determined by biotinylation, streptavidin (SAV) pull-down, and blotting with anti-HA mAb (12CA5). (B) NIH 3T3 cells transfected with N and CSL reporter were cocultured with J1, Dll1, Dll3, mDll3, or parental (L) cell lines and were assayed for luciferase activity. Error bars reflect the SD of the mean from three experiments. RLU, relative luciferase units. (C) Parental C2C12 and cell lines expressing N1 were cocultured with L, J1, Dll1, or Dll3 cells, and myogenesis was monitored by myosin light chain 2 (MLC2) mRNA expression. Loading and transfer of RNA was monitored by methylene blue staining of 18S rRNA. (D) NIH 3T3 cells transfected with N1, CSL reporter, and control or LFng were cocultured with Dll1, J1, rDll3, mDll3, or L cells and were assayed for luciferase activity (n = 3). (E) Parental L, Dll1, or Dll1 + Dll3 cells were cocultured with NIH 3T3 cells transfected with CSL reporter and N or vector. There was no statistically significant difference between Dll1 and Dll1 + Dll3 (n = 3).
Figure 2.
Dll3 does not bind to N. (A) Western Blot (WB) analysis using anti-Fc quantitated Dll3Fc, D1Fc, and D1NTD3Fc for binding assays in B. Numbers represent the dilution of condition media used in the binding assays. (B) 293T cells transfected with vector or N1 were assayed for binding of Fc, Dll3Fc, D1NTD3Fc, and D1Fc by flow cytometry. Fold binding over Fc control is plotted against serial dilutions. (C) Binding of N1Fc to 293T cells transfected with vector or HA-tagged Dll1, Dll3, or D1NTD3 is shown as fold binding over vector control (n = 3). Error bars represent SD. (D) Alignment of the DSL domains of rat and mDll3 with other Dll family members identifies Dll3 as highly divergent. Amino acid sequences conserved in Dll3 are red, whereas amino acid sequences conserved amongst the other Dll-related proteins are blue.
Figure 3.
Dll3 cell autonomously inhibits N signaling. (A) NIH 3T3 cells cotransfected with N1 or N2 and either HA-tagged Dll1, rat Dll3 (rDll3), mDll3, or vector along with a CSL reporter cocultured with Dll1, J1, or L cells. Error bars reflect the SD of the mean from four experiments (*, P < 0.01; **, P < 0.001; ***, P < 0.0001). (B) Western blot of HA-tagged Dll1 and Dll3 from NIH 3T3 cells indicates expression in CSL reporter assays in A. (C) 293T cells cotransfected with N1Δmyc and either vector, Dll1, or Dll3 plasmids and cell surface expression of N1 were analyzed after biotinylation/SAV pull-down and anti-myc (9E10) Western blotting. (D) 293T cells transfected with vector or HA-N1 and either vector, Dll1, or Dll3 plasmids were stained live, and mean fluorescence intensity was determined by FACS. Error bars represent SD. (E) 293T cells cotransfected with Dll1 or Dll3 and N1Δmyc or vector plasmids and cell surface expression of Dll1 or Dll3 were determined by biotinylation/SAV pull-down and anti-HA antibody (12CA5) Western blotting. (F) Lysates from 293T cells transfected with N1 and either HA-tagged Dll1, Dll3, or vector were incubated with N1 antibodies and HA antibody Western blot to detect Dll1 or Dll3 (12CA5; top) or with N1 antibody (93–4; bottom). Middle panel is a HA Western blot of Dll1 and Dll3 from WCL.
Figure 4.
Injection of mDll3 mRNA promotes neurogenesis in X. laevis . Representatives of embryos injected with either synthetic lacZ mRNA alone (A) or in combination with 250 pg Dll1 mRNA (B), 250 pg mDll3 mRNA (C), or 1,000 pg mDll3 mRNA (D) and stained for X-gal (light blue) and β-tubulin (purple) expression. Arrows indicate injection site.
Figure 5.
Dll3 suppresses D1Fc-induced astrocytic differentiation. Embryonic day 11.5 mouse cortical NSCs cotransfected with reporters for GFAP (A) or S100β (B) and either vector or Dll3 were treated with control Fc or D1Fc to induce astrogliogenesis. (C) NSCs cotransfected with GFP and either vector or Dll3 were cultured with D1Fc for 4 d and stained for GFAP. (D) Quantitation of transfected cells expressing GFAP from six independent experiments. (E) GFAP expression in NSCs infected with control (lane 1) or Dll3 adenovirus (lane 2) as determined by Western blotting. (F) Neurogenic stage mouse cortical NSCs cotransfected with NeuroD promoter luciferase construct and vector or Dll3. Promoter activation is plotted as relative luciferase units for six experiments. P < 0.05. *, significant differences between Dll3 and vector; **, significant increase between Fc and D1Fc. Error bars represent SD. AU, arbitrary units. (G) Tubulin (TuJ1) expression in NSCs infected with control (lane 1) or Dll3 adenovirus (lane 2) as determined by Western blotting.
Figure 6.
LFng and Dll3 dynamically modulate N signaling. (A) NIH 3T3 cells cotransfected with N1 and CSL reporter as well as vector or Dll3 with increasing amounts of LFng or control DNA were cocultured with L or Dll1 cells and assayed for luciferase activity. (B) NIH 3T3 cells cotransfected with N1 and CSL reporter as well as control or LFng, and either vector or increasing amounts of Dll3 DNA were cocultured with L or Dll1 cells. P < 0.01. *, a significant difference between vector and Dll3 (low); **, a significant difference between Dll3 (low) and Dll3 (high). n = 5. (C) Lysates from 293T cells cotransfected with N1Δmyc, HA-tagged Dll3, and LFng or control DNA incubated with anti-HA antibody to capture Dll3 immunoprecipitates, which were identified by anti-myc Western blotting to detect N1 (right). Lysate from N1 cells was mixed with equal amounts of D3 lysate and was analyzed alongside other samples (Mix Lys). WCLs were analyzed by anti-myc (top left) and anti-HA Western blotting (bottom left). (D) Parental L or J1 cells cocultured with NIH 3T3 cells that were transfected with N1, CSL reporter, vector, or Dll3 and control or LFng. (*, P < 0.005; **, P < 0.001; n = 7). Error bars represent SD.
Similar articles
- Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis.
Chapman G, Sparrow DB, Kremmer E, Dunwoodie SL. Chapman G, et al. Hum Mol Genet. 2011 Mar 1;20(5):905-16. doi: 10.1093/hmg/ddq529. Epub 2010 Dec 7. Hum Mol Genet. 2011. PMID: 21147753 - A cell autonomous role for the Notch ligand Delta-like 3 in αβ T-cell development.
Hoyne GF, Chapman G, Sontani Y, Pursglove SE, Dunwoodie SL. Hoyne GF, et al. Immunol Cell Biol. 2011 Aug;89(6):696-705. doi: 10.1038/icb.2010.154. Epub 2010 Dec 14. Immunol Cell Biol. 2011. PMID: 21151194 - O-fucosylation of DLL3 is required for its function during somitogenesis.
Serth K, Schuster-Gossler K, Kremmer E, Hansen B, Marohn-Köhn B, Gossler A. Serth K, et al. PLoS One. 2015 Apr 9;10(4):e0123776. doi: 10.1371/journal.pone.0123776. eCollection 2015. PLoS One. 2015. PMID: 25856312 Free PMC article. - Delta-like canonical Notch ligand 3 as a potential therapeutic target in malignancies: A brief overview.
Matsuo K, Taniguchi K, Hamamoto H, Inomata Y, Komura K, Tanaka T, Lee SW, Uchiyama K. Matsuo K, et al. Cancer Sci. 2021 Aug;112(8):2984-2992. doi: 10.1111/cas.15017. Epub 2021 Jun 30. Cancer Sci. 2021. PMID: 34107132 Free PMC article. Review. - The role of Notch in patterning the human vertebral column.
Dunwoodie SL. Dunwoodie SL. Curr Opin Genet Dev. 2009 Aug;19(4):329-37. doi: 10.1016/j.gde.2009.06.005. Epub 2009 Jul 14. Curr Opin Genet Dev. 2009. PMID: 19608404 Review.
Cited by
- Cellular and molecular control of vertebrate somitogenesis.
Miao Y, Pourquié O. Miao Y, et al. Nat Rev Mol Cell Biol. 2024 Jul;25(7):517-533. doi: 10.1038/s41580-024-00709-z. Epub 2024 Feb 28. Nat Rev Mol Cell Biol. 2024. PMID: 38418851 Review. - Species-specific roles of the Notch ligands, receptors, and targets orchestrating the signaling landscape of the segmentation clock.
Ramesh PS, Chu LF. Ramesh PS, et al. Front Cell Dev Biol. 2024 Jan 29;11:1327227. doi: 10.3389/fcell.2023.1327227. eCollection 2023. Front Cell Dev Biol. 2024. PMID: 38348091 Free PMC article. Review. - Notch signalling influences cell fate decisions and HOX gene induction in axial progenitors.
Cooper F, Souilhol C, Haston S, Gray S, Boswell K, Gogolou A, Frith TJR, Stavish D, James BM, Bose D, Kim Dale J, Tsakiridis A. Cooper F, et al. Development. 2024 Feb 1;151(3):dev202098. doi: 10.1242/dev.202098. Epub 2024 Feb 12. Development. 2024. PMID: 38223992 Free PMC article. - Advances in new targets for immunotherapy of small cell lung cancer.
Zheng Z, Liu J, Ma J, Kang R, Liu Z, Yu J. Zheng Z, et al. Thorac Cancer. 2024 Jan;15(1):3-14. doi: 10.1111/1759-7714.15178. Epub 2023 Dec 13. Thorac Cancer. 2024. PMID: 38093497 Free PMC article. Review. - Astrogliosis in multiple sclerosis and neuro-inflammation: what role for the notch pathway?
Mora P, Chapouly C. Mora P, et al. Front Immunol. 2023 Oct 23;14:1254586. doi: 10.3389/fimmu.2023.1254586. eCollection 2023. Front Immunol. 2023. PMID: 37936690 Free PMC article. Review.
References
- Ascano, J.M., L.J. Beverly, and A.J. Capobianco. 2003. The C-terminal PDZ-ligand of JAGGED1 is essential for cellular transformation. J. Biol. Chem. 278:8771–8779. - PubMed
- Barrantes, I.B., A.J. Elia, K. Wunsch, M.H. De Angelis, T.W. Mak, J. Rossant, R.A. Conlon, A. Gossler, and J.L. de la Pompa. 1999. Interaction between N signalling and Lunatic fringe during somite boundary formation in the mouse. Curr. Biol. 9:470–480. - PubMed
- Bulman, M.P., K. Kusumi, T.M. Frayling, C. McKeown, C. Garrett, E.S. Lander, R. Krumlauf, A.T. Hattersley, S. Ellard, and P.D. Turnpenny. 2000. Mutations in the human delta homologue, DLL3, cause axial skeletal defects in spondylocostal dysostosis. Nat. Genet. 24:438–441. - PubMed
- Bush, G., G. diSibio, A. Miyamoto, J.B. Denault, R. Leduc, and G. Weinmaster. 2001. Ligand-induced signaling in the absence of furin processing of N1. Dev. Biol. 229:494–502. - PubMed
- Campos, L.S., A.J. Duarte, T. Branco, and D. Henrique. 2001. mDll1 and mDll3 expression in the developing mouse brain: role in the establishment of the early cortex. J. Neurosci. Res. 64:590–598. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- GM 08946/GM/NIGMS NIH HHS/United States
- R01 NS031885/NS/NINDS NIH HHS/United States
- NS 31885/NS/NINDS NIH HHS/United States
- T32 GM007185/GM/NIGMS NIH HHS/United States
- F31 EB006278/EB/NIBIB NIH HHS/United States
- R37 NS031885/NS/NINDS NIH HHS/United States
- GM 07185/GM/NIGMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous